Palantir a high-risk investment with ’a one-of-a-kind growth and margin model’
In recent transactions reported to the SEC, Adam R. Levy, the Chief Executive Officer of Nexgel , Inc. (NASDAQ:NXGL), sold a total of 2,000 shares of the company’s common stock over two days. The sales, conducted on June 4 and June 5, 2025, were executed at prices of $2.2901 and $2.3231 per share, respectively, amounting to a total value of $4,613. The transactions come as the company, currently valued at $17.8 million, trades near its InvestingPro Fair Value despite challenging financial metrics.
Following these transactions, Levy retains direct ownership of 366,284 shares. According to footnotes provided in the filing, these sales were made for tax planning purposes, and the shares were originally acquired by Levy from the company in October 2019. InvestingPro data reveals the company faces significant challenges, with negative EBITDA of -$3 million and rapidly depleting cash reserves. For detailed analysis of NXGL’s financial health and future prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.
In other recent news, Nexgel Inc. reported a strong performance for the first quarter of 2025, with revenue rising 121% compared to the same period last year, reaching $2.81 million. The company’s earnings before interest, taxes, depreciation, and amortization (EBITDA) loss improved significantly, reducing from -$840,000 to -$540,000. Despite these positive financial results, Nexgel’s stock experienced a decline in aftermarket trading. The company has projected 2025 revenue of $13 million and anticipates achieving cash flow positivity within the year. Nexgel’s strategic focus includes expanding its product offerings and strengthening partnerships, which has positioned it well in the growing hydrogel market. CEO Adam Levy expressed optimism about reaching EBITDA positivity soon, emphasizing the company’s innovation and market expansion. The company is also dealing with potential challenges, such as tariff changes and delays in its partnership with AbbVie (NYSE:ABBV), which could impact projected revenue. However, Nexgel remains confident about its growth prospects and continues to explore new opportunities in contract manufacturing and white-label offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.